These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23328546)

  • 1. Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
    Isobe T; Onn A; Morgensztern D; Jacoby JJ; Wu W; Shintani T; Itasaka S; Shibuya K; Koo PJ; O'Reilly MS; Herbst RS
    J Thorac Oncol; 2013 Feb; 8(2):140-6. PubMed ID: 23328546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
    Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
    Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
    Jacoby JJ; Erez B; Korshunova MV; Williams RR; Furutani K; Takahashi O; Kirkpatrick L; Lippman SM; Powis G; O'Reilly MS; Herbst RS
    J Thorac Oncol; 2010 Jul; 5(7):940-9. PubMed ID: 20512076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
    Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY
    Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
    Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
    Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
    Kaufmann SH; Kalemkerian GP; Jasti R; Mabry M
    Biochem Pharmacol; 1995 Dec; 50(12):1987-93. PubMed ID: 8849324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
    Onn A; Isobe T; Itasaka S; Wu W; O'Reilly MS; Ki Hong W; Fidler IJ; Herbst RS
    Clin Cancer Res; 2003 Nov; 9(15):5532-9. PubMed ID: 14654533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
    Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
    Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
    Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED
    Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
    Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
    Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.
    Marini AM; Fridman R; Kanemoto T; Martin GR; Guo Y; Passaniti A
    J Natl Cancer Inst; 1992 Oct; 84(20):1582-7. PubMed ID: 1328660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
    Kinehara Y; Minami T; Kijima T; Hoshino S; Morimura O; Otsuka T; Hayama Y; Fukushima K; Takeuchi Y; Higashiguchi M; Miyake K; Hirata H; Nagatomo I; Inoue K; Takeda Y; Kida H; Kumanogoh A
    Lung Cancer; 2015 Mar; 87(3):321-5. PubMed ID: 25601188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.